Aortic & peripheral vascular disease
Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease
Main findingResult — go to the resultHazard ratio 0.54 95% CI 0.46–0.64Authors' conclusion
Compared to statin monotherapy, an intensified lipid-lowering strategy (ie, ezetimibe plus statins), significantly reduced the incidence of major lower limb amputation and all-cause mortality in real-world patients with LEAD.
Study context
- Population
- Patients aged ≥18 years diagnosed with lower extremity artery disease (LEAD), 2013 to 2022, excluding those with recent acute coronary syndrome or strokepatients in each group after propensity score matching
- Participants
- 4,204 patients
- Exposure
- Ezetimibe plus statins vs statin monotherapy
- Statins plus ezetimiben = 4,204
- Statin monotherapyn = 4,204reference
- Outcome
- Composite of:
- Major lower limb amputation
- All-cause death (cumulative incidence)
- Follow-up
- 12 months
Methodological detailspropensity score matching, TriNetX global health care database
- Propensity score matching
- TriNetX global health care database
Main finding
As reported in the abstract
Hazard ratio
0.54
95% CI 0.46–0.64
P < 0.001
By group
Statins plus ezetimibevs statin monotherapy
HR 0.54 (95% CI 0.46–0.64); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Statins plus ezetimibe | Statin monotherapy | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Major lower limb amputationLower with combination therapy | 2.7% | 4.6% | 0.57 (0.45–0.72) | P < 0.001 | |
| All-cause deathLower with combination therapy | 3.4% | 6.3% | 0.52 (0.42–0.65) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Subgroup analyses
- Consistent effects across all subgroups
Original publication
Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease. JACC Adv. Published 18 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →